Aminex Therapeutics Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
7
- Latest Deal Type
-
Series D
- Latest Deal Amount
-
$3.4M
- Investors
-
1
Aminex Therapeutics General Information
Description
Operator of a drug development company intended to focus on advancing novel immunotherapy for cancer treatment and cure. The company's immuno-oncology approach significantly reduces the uptake and production of polyamines and in turn, myeloid-derived suppressor cells in the tumor microenvironment, allowing for activation of the innate immune system to attack solid tumors, enabling patients' innate immune systems to attack solid tumors in their bodies.
Contact Information
Website
www.aminextx.comCorporate Office
- 6830 North East Bothell Way
- Suite C-139
- Kenmore, WA 98028
- United States
Corporate Office
- 6830 North East Bothell Way
- Suite C-139
- Kenmore, WA 98028
- United States
Aminex Therapeutics Timeline
Aminex Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC (Series D) | 15-Sep-2022 | $3.4M | Completed | Clinical Trials - Phase 1 | ||
| 5. Later Stage VC (Series C) | 18-Aug-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series B) | 31-May-2018 | Completed | Clinical Trials - Phase 1 | |||
| 3. Later Stage VC (Series A) | 15-Jul-2015 | Completed | Pre-Clinical Trials | |||
| 2. Seed Round | 15-Jun-2014 | $1.7M | $1.7M | Completed | Startup | |
| 1. Grant | 10-Nov-2010 | $244K | Completed | Startup |
Aminex Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | ||||||||
| Series A | 7,000,000 | $0.000100 | 6% | $0.7 | $0.7 | 1x | $0.7 | 17.5% |
| Seed | 6,034,346 | $0.000100 | 6% | $0.35 | $0.35 | 1x | $0.35 | 15.09% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Aminex Therapeutics Comparisons
Industry
Financing
Details
Aminex Therapeutics Competitors (40)
One of Aminex Therapeutics’s 40 competitors is Pyxis Oncology, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Pyxis Oncology | Formerly VC-backed | Boston, MA | ||||
| Navrogen | Venture Capital-Backed | Cheyney, PA | ||||
| Verseau Therapeutics | Venture Capital-Backed | Bedford, MA | ||||
| NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Aurora Biopharma | Angel-Backed | Cambridge, MA |
Aminex Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aminex Therapeutics Patents
Aminex Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230321012-A1 | Methods to treat cancer with amxt 1501 and dfmo | Inactive | 01-Dec-2021 | ||
| EP-4221698-A1 | Combination drug substance of polyamine transport inhibitor and dfmo | Pending | 30-Sep-2020 | ||
| US-11865095-B2 | Combination drug substance of polyamine transport inhibitor and dfmo | Active | 30-Sep-2020 | ||
| AU-2021354039-A1 | Combination drug substance of polyamine transport inhibitor and dfmo | Pending | 30-Sep-2020 | ||
| US-20220096412-A1 | Combination drug substance of polyamine transport inhibitor and dfmo | Active | 30-Sep-2020 | A61K31/198 |
Aminex Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aminex Therapeutics Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| United States Department of the Treasury | Government |
Aminex Therapeutics FAQs
-
When was Aminex Therapeutics founded?
Aminex Therapeutics was founded in 2009.
-
Where is Aminex Therapeutics headquartered?
Aminex Therapeutics is headquartered in Kenmore, WA.
-
What is the size of Aminex Therapeutics?
Aminex Therapeutics has 7 total employees.
-
What industry is Aminex Therapeutics in?
Aminex Therapeutics’s primary industry is Drug Discovery.
-
Is Aminex Therapeutics a private or public company?
Aminex Therapeutics is a Private company.
-
What is the current valuation of Aminex Therapeutics?
The current valuation of Aminex Therapeutics is .
-
What is Aminex Therapeutics’s current revenue?
The current revenue for Aminex Therapeutics is .
-
How much funding has Aminex Therapeutics raised over time?
Aminex Therapeutics has raised $32.5M.
-
Who are Aminex Therapeutics’s investors?
United States Department of the Treasury has invested in Aminex Therapeutics.
-
Who are Aminex Therapeutics’s competitors?
Pyxis Oncology, Navrogen, Verseau Therapeutics, NexImmune, and Aurora Biopharma are some of the 40 competitors of Aminex Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
